

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20221

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/783,320	02/15/2001	D. Wade Walke	LEX-0137-USA	3185
24231 1 EVICON (7590 11/28/2001 GENETICS INCORI		EXAM	INER
4000 RESEA	RCH FOREST DRIVI LANDS, TX 77381		RAMIREZ,	DELIA M
1112 0 0 =			ART UNIT	PAPER NUMBER
			1652	ð
			DATE MAILED: 11/28/200	1 b

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summary	09/783,320	WALKE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Delia M. Ramirez	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply	VIC CET TO EVDIDE 4 MONTH	H(S) EROM				
A SHORTENED STATUTORY PERIOD FOR REPI THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu - Any reply received by the Office later than three months after the mailie earned patent term adjustment. See 37 CFR 1.704(b). Status	. 136 (a). In no event, however, may a reply be ply within the statutory minimum of thirty (30) d will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	timely filed ays will be considered timely. m the mailing date of this communication. IED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on	 ·					
 /	his action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-10</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claims 1-10 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Exam	iner.					
10) The drawing(s) filed on is/are objected						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. § 119						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14)⊠ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
Attachment(s)						
15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper Not	19) Notice of Infor	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)				

Application/Control Number: 09/783,320

Art Unit: 1652

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3, drawn to a polynucleotide according to SEQ ID NO: 1 and a polynucleotide encoding the polypeptide of SEQ ID NO: 2, classified in class 536, subclass 23.2.
- II. Claim 4, drawn to a polynucleotide encoding the polypeptide of SEQ ID NO: 4, classified in class 536, subclass 23.2.
- III. Claim 5, drawn to a polynucleotide encoding the polypeptide of SEQ ID NO: 6, classified in class 536, subclass 23.2.
- IV. Claims 6-8, drawn to a polynucleotide according to SEQ ID NO: 45 and a polynucleotide encoding the polypeptide of SEQ ID NO: 46, classified in class 536, subclass 23.2.
- V. Claim 9, drawn to a polynucleotide encoding the polypeptide of SEQ ID NO: 38, classified in class 536, subclass 23.2.
- VI. Claim 10, drawn to a polynucleotide encoding the polypeptide of SEQ ID NO:30, classified in class 536, subclass 23.2.

The inventions are distinct, each from the other because of the following reasons:

Groups I-VI are directed to different products related by virtue of encoding polypeptides with kinase activity. However, they are patentably distinct inventions for the following reasons.

Groups I-VI are directed to different nucleic acid molecules with different sequences, structures,

Application/Control Number: 09/783,320

Art Unit: 1652

and use, are not required one for the other, and encode a different polypeptide with unrelated amino acid sequences. Furthermore, a search and examination of all these Groups would result in an undue burden since the searches are not co-extensive. Accordingly, restriction is deemed proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement can be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Certain papers related to this application may be submitted to Art Unit 1652 by facsimile transmission. The FAX number is (703) 308-4556. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 CFR 1.6(d)). NOTE: If Applicant submits a paper by FAX, the original copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED, so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez whose telephone number is (703) 306-0288. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM.

Application/Control Number: 09/783,320

Art Unit: 1652

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy can be reached on (703) 308-3804. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

DR November 16, 2001 Delia M. Ramirez, Ph.D. Patent Examiner Art Unit 1652

PONNATHAPU ACHUTAMURTHY SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600